Life Sciences Tools and Services
Company Overview of Furiex Pharmaceuticals, Inc.
Furiex Pharmaceuticals, Inc. operates as a drug development company that is involved in compound development and collaboration activities primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company holds rights to royalties and regulatory and sales-based milestone payments for alogliptin, alogliptin combination products, and SYR-472 (trelagliptin) for the treatment of Type-2 diabetes, which are marketed under the Nesina and Liovel names in Japan, as well as under the Nesina, Oseni, and Kazano names in the United States. It also owns rights to royal...
3900 Paramount Parkway
Morrisville, NC 27560
Founded in 1998
Key Executives for Furiex Pharmaceuticals, Inc.
Chief Financial Officer, Principal Accounting Officer and Vice President of Strategic Development
Senior Vice President of Clinical Development & Operations
Associate Director of Preclinical Development
Executive Director of Clinical Operations
Compensation as of Fiscal Year 2015.
Furiex Pharmaceuticals, Inc. Key Developments
Furiex Pharmaceuticals, Inc.(NasdaqGM:FURX) dropped from Russell 2000 Index
Jul 3 14
Furiex Pharmaceuticals, Inc. will be removed from the Russell 2000 Index.
Furiex Pharmaceuticals, Inc.(NasdaqGM:FURX) dropped from Russell 3000 Index
Jul 3 14
Furiex Pharmaceuticals, Inc. will be removed from the Russell 3000 Index.
Furiex Pharmaceuticals, Inc.(NasdaqGS:FURX) dropped from NASDAQ Composite Index
Jul 2 14
Furiex Pharmaceuticals, Inc. will be removed from the NASDAQ Composite Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries